Patents Assigned to TARGETGENE BIOTECHNOLOGIES LTD.
  • Publication number: 20240148771
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Application
    Filed: May 15, 2023
    Publication date: May 9, 2024
    Applicant: TARGETGENE BIOTECHNOLOGIES LTD.
    Inventors: Yoel Moshe SHIBOLETH, Dan Michael WEINTHAL
  • Patent number: 11690866
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: July 4, 2023
    Assignee: TARGETGENE BIOTECHNOLOGIES LTD.
    Inventors: Yoel Moshe Shiboleth, Dan Michael Weinthal
  • Patent number: 11458157
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Grant
    Filed: December 16, 2012
    Date of Patent: October 4, 2022
    Assignee: Targetgene Biotechnologies Ltd.
    Inventors: Yoel Moshe Shiboleth, Dan Michael Weinthal
  • Patent number: 11278560
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: March 22, 2022
    Assignee: TARGETGENE BIOTECHNOLOGIES LTD.
    Inventors: Yoel Moshe Shiboleth, Dan Michael Weinthal
  • Patent number: 10220052
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: March 5, 2019
    Assignee: TARGETGENE BIOTECHNOLOGIES LTD
    Inventors: Yoel Moshe Shiboleth, Dan Michael Weinthal
  • Publication number: 20170233752
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 17, 2017
    Applicant: TARGETGENE BIOTECHNOLOGIES LTD.
    Inventors: Yoel Moshe SHIBOLETH, Dan Michael WEINTHAL